Results 111 to 120 of about 1,738 (148)

Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence. [PDF]

Mediators Inflamm
Heidari A, Mazid AS, Behroozfar M, Ghotbi N, Fathabadi F, Eghbali S, Heidari N.   +6 more
europepmc   +1 more source

Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors. [PDF]

World J Gastroenterol
Liu WN, Dai MS, Lin F, Lin GM.
europepmc   +1 more source

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Hematol
Buchrits S, Trieman G, Giladi O, Hofstetter L, Gurion R, Granot G, Shacham-Abulafia A, Raanani P, Gafter-Gvili A.   +8 more
europepmc   +1 more source

Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895. [PDF]

Cancer Res Commun
Stromatt JC, Ahmed EA, Drabison T, Nepal MR, Chowdhury AT, Orwick SJ, Buelow DR, Eisenmann ED, Huang KM, Sparreboom A, Baker SD.   +10 more
europepmc   +1 more source

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Blood
Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG.   +26 more
europepmc   +1 more source

Zanubrutinib plus salvage chemotherapy in patients with refractory/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study. [PDF]

Ann Hematol
He S, Sun J, Zhong D, Rong C, Liao C, Tan X.   +5 more
europepmc   +1 more source

Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia. [PDF]

BMC Infect Dis
Dai B, Han S, Shen Y, Li Z, Chen S, Wang Z, Yuan Y, Zhang R, Wang C, Zheng J, Liang Q, Wang Q, Zhang Y, Zhang X, Wang F, Jin Y.   +15 more
europepmc   +1 more source

High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies. [PDF]

Haematologica
Al-Sawaf O.
europepmc   +1 more source

BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. [PDF]

Cancer Med
Luo W, Zhang Y, Li C, Xu J, Wu Z, Wang X, Kang Y, Liao D, Kou H, Xie W, Xiong W, Deng J, Mei H, Hu Y.   +13 more
europepmc   +1 more source

Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus

Case Medical Research, 2019
Case Medical Research
  +5 more sources